BIIB Said BG-12 Psoriasis Study Meets Primary Endpoint

April 7, 2005 8:10 AM EDT Send to a Friend
Biogen Idec (NASDAQ: BIIB) and Fumapharm AG today announced results from a Phase III ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login